The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
An unusual new ‘homologous series’ of barium compounds forms a potentially infinite sequence of related structures with predictable unit cells. The US team behind this discovery says that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback